NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · NMRD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nemaura Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nemaura Medical Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nemaura Medical Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles. The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:26 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Nov 15, 2022 | -$0.170.0% vs estimate | $74.03K-44.48% vs estimate |
|---|
| Q1 2023 | Aug 15, 2022 | -$0.17-6.25% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2022 | Jun 30, 2022 | -$0.150.0% vs estimate | $320.28K-28.83% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$19.35+$0.67 (+3.59%)
Precipio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
$1.74-$0.01 (-0.57%)
Biomerica, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.82% below the high.
$4.88+$0.14 (+2.95%)
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
$0.73-$0.08 (-10.09%)
Ainos, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.21% below the high.
$0.54-$0.02 (-3.6%)
INVO Fertility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.98% below the high.
$1.03$0.00 (0.0%)
ENvue Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.78% below the high.
